SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia. 2004;24(Suppl. 1):1-151.
  • 2
    MacGregor EA. Menstrual migraine: Towards a definition. Cephalalgia. 1996;16:11-21.
  • 3
    Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: Results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics. 2003;111:844-850.
  • 4
    McKinlay SM. The normal menopause transition: An overview. Maturitas. 1996;23:137-145.
  • 5
    Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81:1495-1501.
  • 6
    SilbersteinSD, FreitagF, BigalM. Migraine Treatment. Wolff's Headache, 8th edn. New York, NY: Oxford University Press; 2008:177-292.
  • 7
    Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
  • 8
    Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study. Neurology. 1995;45:1076-1082.
  • 9
    Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: A clinico-epidemiologic study. Maturitas. 1993;17:31-37.
  • 10
    Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther. 2004;11:130-140.
  • 11
    Tepper S. Tailoring management strategies for the patient with menstrual migraine: Focus on prevention and treatment. Headache. 2006;46(Suppl. 2):S61-S68.
  • 12
    Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006;27(Suppl. 2):S193-S197.
  • 13
    Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
  • 14
    Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel, C. The French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12:774-781.
  • 15
    Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: Two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:414-421.
  • 16
    Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol. 1995;86:911-916.
  • 17
    Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102:835-842.
  • 18
    Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: A randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44:120-130.
  • 19
    Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studies. Clin Ther. 1999;21:475-491.
  • 20
    D'Alessandro R, Gamberini G, Lozito A, et al. Menstrual migraine: Intermittent prophylaxis with a timed-released pharmacological formulation of dihydroergotamine. Cephalalgia. 1983;3(Suppl. 1):156-158.
  • 21
    Allais G, Bussone G, De Lorenzo C, et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: Pathophysiological and clinical considerations. Neurol Sci. 2007;28(Suppl. 2):S225-S228.
  • 22
    Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache. 1990;30:705-709.
  • 23
    Newman L. Understanding the causes and prevention of menstrual migraine: The role of estrogen. Headache. 2007;47(Suppl. 2):S86-S94.
  • 24
    Silberstein SD, Bradley K. DHE-45® in the prophylaxis of menstrually related migraine. Cephalalgia. 1996;16:371.
  • 25
    Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: A randomized, double-blind, placebo-controlled study. Headache. 2001;41:248-256.
  • 26
    Moschiano F, Allais G, Grazzi L. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci. 2005;26(Suppl. 2):s162-s166.
  • 27
    Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307-309.
  • 28
    Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache. 1991;31:298-301.
  • 29
    Martin V, Brandes J. IMED Communications. Strategies for optimizing the management of menstrual migraine. J Fam Pract. 2005;54:S1-S7.
  • 30
    Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985;25:320-324.
  • 31
    Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
  • 32
    Gaffield ME, Curtis KM, Mohllajee AP, Peterson HB. Medical eligibility criteria for new contraceptive methods: Combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant. Contraception. 2006;73:134-144.
  • 33
    Stang A, Schwingl P, Rivera R. New contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community-based programmes. Bull World Health Organ. 2000;78:1015-1023.
  • 34
    Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The international headache society task force on combined oral contraceptives & hormone replacement therapy. Cephalalgia. 2000;20:155-156.
  • 35
    ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. no. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453-1472.
  • 36
    Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation. 2006;113:2425-2434.
  • 37
    Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006;163:589-599.
  • 38
    Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: Toward resolving the discrepancy between observational studies and the women's health initiative clinical trial. Am J Epidemiol. 2005;162:404-414.
  • 39
    De Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous estradiol. Br Med J. 1986;293:1540.
  • 40
    Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: A double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2:113-120.
  • 41
    MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study. Neurology. 2006;67:2159-2163.
  • 42
    Smite MG, Van Der Meer YG, Pfeil JP, et al. Perimenstrual migraine: Effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34:103-106.
  • 43
    Pradalier A, Vincent D, Beaulieu P, Baudesson G, Launay J-M. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: RoseFC, ed. New Advances in Headache Research, 4th edn. London: Smith-Gordon; 1994:129-132.
  • 44
    Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349-353.
  • 45
    Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
  • 46
    Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas. 2001;38:157-163.